INVO Bioscience, Inc. - התחייבויות לטווח ארוך של החברה INVO

INVO Bioscience, Inc. (INVO) is developing affordable infertility treatments through the INVOcell system, targeting the ART segment. This chart of the share price on GURU.Markets confirms the asset's dynamics, where the indicator stands at -0.04. Management aims to expand its network of proprietary centers and monetize innovations. However, due to high marketing expenses coupled with low revenue, the company is burning cash and securing loans.

Weak pricing power at INVO Bioscience, Inc. (INVO) due to the slow adoption of IVF technologies is limiting the inflow of operating capital. When analyzing the company's long-term debt levels, an investor assesses the aggregate of all liabilities with a maturity exceeding one year. This indicator quantifies the expansion financing strategy and the reliance on external borrowings. An upward trend in this curve amid stagnating revenues signals a risk of insolvency. Monitoring this metric allows for the determination of the business model's sustainability.